Visible-Light-Controlled Histone Deacetylase Inhibitors for Targeted Cancer Therapy
Journal of Medicinal Chemistry · 2023
DOI: 10.1021/acs.jmedchem.2c01713 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Laia Josa-Culleré und 1 weiteren Autor:innen. Beteiligte Einrichtung: MCS, Laboratory of Medicinal Chemistry & Synthesis, Department of Biological Chemistry, Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), Jo…. Hauptthemen laut MEDLINE: Neoplasms, Antineoplastic Agents. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: H2020 Marie Sklodowska-Curie Actions, Generalitat de Catalunya, Agencia Estatal de Investigaci?n,Ministerio de Ciencia, Innovaci?n y Universidades.
Abstract (Originalsprache)
The lack of selectivity of anticancer drugs limits current chemotherapy. Light-activatable drugs, whose activity can be precisely controlled with external light, could provide a more localized action of the drugs in the tumor, thus decreasing side effects and increasing efficacy. Herein, we introduce a series of photoswitchable azobenzene histone deacetylase inhibitors (HDACis) whose activity can be controlled by external visible light. Initial HDACis isomerized under ultraviolet light and were up to >50-fold more active under illumination than in the dark in enzyme assays. These were then optimized toward compounds responding to more permeable and less harmful green light by introducing o-halogen atoms into the azobenzene. Selected compounds decreased cell viability only under illumination in four different cancer cell lines. Overall, we present photoswitchable HDACis with optimized activation wavelengths, which inhibit enzyme activity and cell viability only upon illumination with visible light, contributing to the still limited toolbox of photoswitchable anticancer drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- MCS, Laboratory of Medicinal Chemistry & Synthesis, Department of Biological Chemistry, Institute for Advanced Chemistry of Catalonia (IQAC-CSIC), Jordi Girona 18-26, 08034Barcelona, Spain.
ORCID-Profile: Laia Josa-Culleré, Amadeu Llebaria
Förderung
- H2020 Marie Sklodowska-Curie Actions
- Generalitat de Catalunya
- Agencia Estatal de Investigaci?n,Ministerio de Ciencia, Innovaci?n y Universidades
Zitieren
APA
Josa-Culleré, L., & Llebaria, A. (2023). Visible-Light-Controlled Histone Deacetylase Inhibitors for Targeted Cancer Therapy. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.2c01713
Vancouver
Josa-Culleré L, Llebaria A. Visible-Light-Controlled Histone Deacetylase Inhibitors for Targeted Cancer Therapy. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.2c01713
BibTeX
@article{JosaCuller2023,
author = {Josa-Culleré, Laia and Llebaria, Amadeu},
title = {Visible-Light-Controlled Histone Deacetylase Inhibitors for Targeted Cancer Therapy},
journal = {Journal of Medicinal Chemistry},
year = {2023},
doi = {10.1021/acs.jmedchem.2c01713}
}
EUVIMED